أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - ceftazidime -

مالطا - الإنجليزية - Medicines Authority

elpen pharmaceutical co. inc. 95 marathonos ave., 190 09 pikermi, attica, greece - cefuroxime - powder for solution for injection - cefuroxime 750 mg - antibacterials for systemic use

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ezetimibe, quantity: 10 mg; atorvastatin calcium trihydrate, quantity: 20.681 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium lauryl sulfate; lactose monohydrate; povidone; calcium carbonate; microcrystalline cellulose; hyprolose; lactose; sodium stearylfumarate; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - atorvastatin calcium trihydrate, quantity: 10.341 mg (equivalent: atorvastatin, qty 10 mg); ezetimibe, quantity: 10 mg - tablet, film coated - excipient ingredients: crospovidone; sodium stearylfumarate; lactose; povidone; sodium lauryl sulfate; colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; calcium carbonate; hyprolose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ezetimibe, quantity: 10 mg; atorvastatin calcium trihydrate, quantity: 41.363 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; sodium stearylfumarate; sodium lauryl sulfate; colloidal anhydrous silica; lactose; calcium carbonate; microcrystalline cellulose; crospovidone; povidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ezetimibe, quantity: 10 mg; atorvastatin calcium trihydrate, quantity: 82.725 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: povidone; sodium stearylfumarate; colloidal anhydrous silica; lactose; hyprolose; lactose monohydrate; microcrystalline cellulose; calcium carbonate; sodium lauryl sulfate; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).